---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-045176"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2023-08-30T23:59:59+00:00"
generated_at: "2026-06-11T01:57:42.166066+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alkermes settles VIVITROL patent litigation with Teva; generic entry January 2027

## Summary
- Teva granted license to market generic VIVITROL in U.S. starting Jan 15, 2027, or earlier under certain circumstances.
- Settlement resolves lawsuit filed Sep 2020; trial completed Mar 2023; patent expires 2029.
- Agreement subject to FTC and DOJ review; parties will file joint stipulation to dismiss litigation.
- Financial terms not disclosed; license is non-exclusive, royalty-free, limited to Teva's ANDA product.

## SEC filing metadata
- accession: 0000950170-23-045176
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2023-08-30T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/0000950170-23-045176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/alks-20230829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-045176
- JSON: https://secwatch.observer/filing/0000950170-23-045176.json
- Plain text: https://secwatch.observer/filing/0000950170-23-045176.txt

## Key facts
- Material Agreements
  Alkermes plc. entered into Confidential Settlement and License Agreement with Teva Pharmaceuticals USA, Inc. (effective 2023-08-29).
  - Action: entry
  - Agreement: settlement
  - Counterparty: Teva Pharmaceuticals USA, Inc.
  - Effective: 2023-08-29
  source text: On August 29, 2023, Alkermes, Inc. and Alkermes Pharma Ireland Limited, subsidiaries of Alkermes plc (together, “Alkermes”), entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Teva Pharmaceuticals USA, Inc. (“Teva”, and together with Alkermes, the “parties”) relating to Alkermes’ product VIVITROL ® (naltrexone for extended-release injectable suspension).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/0000950170-23-045176-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.